Pubblicazioni 2025-2026

2026

Antonuzzo L, Lavacchi D, Spada F, Marconcini R, Gelsomino F, Amoroso V, Cosso F, Pellegrini E, Scolari F, Sparano C, Massaro G, Giommoni E, Messerini L, Rossini D, Brugia M, Di Costanzo F, Boni L, Milione M, Pillozzi S, Fazio N; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: results from the MAVERIC phase II trial.

Oncologist. 2026 Feb 5;31(3):oyaf432. doi: 10.1093/oncolo/oyaf432.PMID: 41572426 

Biagioni C, Fimereli D, Irrthum A, Guerrero-Zotano A, Piccart M, Cameron D, Caballero C, Raimbault A, Martins-Branco D, Romagnoli D, Agostinetto E, Venet D, Llinas-Bertran A, Seoane JA, Zoppoli G, Vivancos A, Vingiani A, Oliveira M, Curigliano G, Crestani T, Sotiriou C, Nili Gal-Yam E, Hilbers FS, Aftimos P, Benelli M.

Molecular and Clinical Analyses of Gene Fusions Identify Therapeutic Targets in Paired Primary and Metastatic Breast Cancer from the AURORA Program (BIG 14-01).

Clin Cancer Res. 2026 Mar 2;32(5):947-962. doi: 10.1158/1078-0432.CCR-25-2707.PMID: 41427961

2025

Pinto C, Castoro C, De Vita F, Luporini AG, Maiello E, Mazzarotto R, Scarpa A, Caccialanza R, Damato A; Italian Multidisciplinary Panel.

Diagnostic and therapeutic appropriateness in different stages of esophageal/GEJ cancers. The FICOG project.

Future Oncol. 2025 Oct;21(23):3027-3041. doi: 10.1080/14796694.2025.2551482. Epub 2025 Sep 9.PMID: 40923994

Damato A, Maglietta G, Antonuzzo L, Berardi R, Buonadonna A, Brighi N, Cinieri S, Di Micco C, Gelsomino F, Grossi F, Martinelli E, Cesario S, Pusceddu S, Spada F, Iachetta F, Gervasi E, Ciardiello G, Normanno N, Pinto C.

Agnostic phase II, multicenter, single-arm study with DURVAlumab plus carboplatin or cisplatin and etoposide as first-line treatment in extensive stage - Extrapulmonary Small Cell Carcinoma (EPSCC) patients - DURVASCC trial (GOIRC-01-2021).

BMC Cancer. 2025 Nov 12;25(1):1763. doi: 10.1186/s12885-025-15112-w.PMID: 41225446 

Toss A, Zattarin E, Moscetti L, Dominici M.

Bridging language barriers in global oncology: toward more inclusive scientific communication.

ESMO Open. 2025 Dec;10(12):105911. doi: 10.1016/j.esmoop.2025.105911. Epub 2025 Nov 18.PMID: 41259898. No abstract available.

Sarti S, Viansone AA, Serra O, Casadei C, Cecconetto L, Di Menna G, Farolfi A, Gianni C, Mariotti M, Merloni F, Palleschi M, Sirico M, Zoppoli G, Musolino A.

Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions.

Cancers (Basel). 2025 Nov 7;17(22):3597. doi: 10.3390/cancers17223597.PMID: 41300964. Review.

Zattarin E, Moscetti L, D’Agostino E, Bertolotti A, Sperduti I, Chiavelli C, Canino F, Piacentini F, Cortesi L, Dominici D, Toss A

Impact of Ethnicity on Breast Cancer Outcome: A Systematic Review and Meta-Analysis of Randomized Phase III Trials of the Last Decade

JCO Glob Oncol. 2025 Jul:11:e2500139. doi: 10.1200/GO-25-00139. Epub 2025 Jul 1.

Moscetti, E. Barbieri, E. Zattarin, P. Vici, G. Zoppoli, A. Musolino, S. Natalizio, F. Canino, F. Ravera, L. Filomeno, T. Arcuri, C. Omarini, F. Piacentini, M. Barbolini, L. Cortesi, F. Caggia, M. Civallero, M. Dominici & A. Toss

Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019

ESMO Real World Data and Digital Oncology. Volume 8, June 2025, 100154: 1-9. doi.org/10.1016/j.esmorw.2025.100154

Shinn E, Zahrieh D, DeMichele A, Zdenkowski N, Lemieux J, Mao J, Bjelic-Radisic V, Naughton MJ, Pfeiler G, Gelmon K, Balko JM, Egle D, Zoppoli G, Traina T, Jimenez MM, Novoa SA, Haddad T, Chan A, Ring A, Wolff A, Symmans WF, Ponce Lorenzo J, Sabanathan D, Burstein HJ, Nowecki ZI, Pristauz-Telsnigg G, Brufsky A, Bellet-Ezquerra M, Foukakis T, Novik Y, Rubovszky G, Singer CF, Muehlbacher K, Filho OM, Goulioti T, Law E, Partridge AH, Carey LA, Zoroufy A, Hlauschek D, Fesl C, Mayer EL, Gnant M.

Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer

Breast Cancer Res Treat. 2025 Jun;211(2):385-397. doi: 10.1007/s10549-025-07653-2. Epub 2025 Mar 27.

Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.

Shinn E, Zahrieh D, DeMichele A, Zdenkowski N, Lemieux J, Mao J, Bjelic-Radisic V, Naughton MJ, Pfeiler G, Gelmon K, Balko JM, Egle D, Zoppoli G, Traina T, Jimenez MM, Novoa SA, Haddad T, Chan A, Ring A, Wolff A, Symmans WF, Lorenzo JP, Sabanathan D, Burstein HJ, Nowecki ZI, Pristauz-Telsnigg G, Brufsky A, Bellet-Ezquerra M, Foukakis T, Novik Y, Rubovszky G, Singer CF, Muehlbacher K, Filho OM, Goulioti T, Law E, Partridge AH, Carey LA, Zoroufy A, Hlauschek D, Fesl C, Mayer EL, Gnant M.

Breast Cancer Res Treat. 2026 Feb 18;216(2):12. doi: 10.1007/s10549-026-07896-7.PMID: 41706231 No abstract available.

Lamberti G, Rihawi K, Mazzoni F, Riccardi F, Follador A, Tiseo M, Frassoldati A, Colantonio I, Bonetti A, Genova C, Giardina D, Bertolini F, Cinieri S, Pasello G, Brighenti M, Andrini E, Tognetto M, Boni L, Ardizzoni A; GOIRC group.

Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study.

J Immunother Cancer. 2025 May 7;13(5):e010694. doi: 10.1136/jitc-2024-010694.

Facchinetti F, Camerini A, Bennati C, Bordi P, De Carlo E, Mazzoni F, Metro G, Bertolini F, Longo L, Ricciardi S, Pilotto S, Giardina D, Passiglia F, Scotti V, Piacentini P, Frega S, Calabrò L, Guida A, Grosso MA, Longobardi J, Merlini A, Cosso F, Leonetti A, Gariazzo E, Guaitoli G, Belluomini L, Bearz A, Tognetto M, Bria E, Cortinovis DL, Novello S, Di Maio M, Tiseo M

A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)

Lung Cancer. 2025 Jun;204:108580. doi: 10.1016/j.lungcan.2025.108580. Epub 2025 May 17.PMID: 40382877

Pellegrino B, Giovanardi F, Tibaldi C, Moscetti L, Vingiani A, Calabrò L, Zoppoli G, Didone S, Ferrando L, Franceschi E, Todeschini R, Tognetto M, Leonetti A, Minari R, Tommasi C, Serra O, Boni L, Pruneri G, Musolino A.

Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

Lung Cancer. 2025 Jan;199:108059. doi: 10.1016/j.lungcan.2024.108059. Epub 2024 Dec 15.

Gelsomino F, Boni L, Tiseo M, Ricciardi S, Rocco D, Cortinovis DL, Proietto M, Cogoni A, Pasello G, Camerini A, Sperandi F, Colantonio I, Metro G, Mazzoni F, Baldini E, Veccia A, Bennicelli E, Cecilia Bettini A, Tognetto M, Ardizzoni A.

An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016

Lung Cancer. 2025 Jan;199:108059. doi: 10.1016/j.lungcan.2024.108059. Epub 2024 Dec 15.

Maglietta G, Damato A, Finotto S, Mandarà M, Tamberi S, Grisanti S, Brighenti M, Tiseo M, Montesarchio V, Catino A, Gelsomino F, Giovanardi F, Antonuzzo L, Romagnani A, Gervasi E, Di Maio M, Pinto C.

Impact of edoxaban-related adverse events in patients with cancer experiencing venous thromboembolism during antineoplastic therapy: Results of the phase IV EDOI study (GOIRC-05–2018)

Eur J Cancer 2025 Mar 26:219:115296.

doi: 10.1016/j.ejca.2025.115296. Epub 2025 Feb 9. 

Belluzzi L, Martinelli G, Medici B, Farina A, Martinelli E, Canino F, Caggia F,  Molinaro A, Barbolini M, Tamburrano F, Moscetti L, Piacentini F, Dominici M, Omarini C.

Update on Pulmonary Toxicity Induced by New Breast Cancer Treatments

Breast Cancer (Dove Med Press). 2025 Jan 21;17:53-66. doi: 10.2147/BCTT.S489419. eCollection 2025.PMID: 39867812.

Ignatiadis M, Bailey A, McArthur H, El-Abed S, de Azambuja E, Metzger O, Chui SY, Dieterich M, Perretti T, Shearer-Kang E, Molinero L, Steger GG, Jassem J, Lee SC, Higgins M, Zarba J, Schmidt M, Gomez H, Guerrero Zotano A, Moscetti L, Chiu J, Munzone E, Ben-Baruch NE, Bajetta E, Ohno S, Im SA, Werutsky G, Gal-Yam EN, Gonzalez Farre X, Tseng LM, Jacot W, Gluz O, Shao Z, Shparyk Y, Zimina A, Winer E, Cameron DA, Viale G, Saji S, Gelber R, Piccart M.

Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial

JAMA. 2025 Jan 30:e2426886. doi: 10.1001/jama.2024.26886. Online ahead of print.PMID: 39883436